BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34530170)

  • 1. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma.
    Khriguian J; Patrocinio H; Andonian S; Aprikian A; Kassouf W; Tanguay S; Cury FL
    Pract Radiat Oncol; 2022; 12(1):e34-e39. PubMed ID: 34530170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
    Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.
    Grasso M; Fishman AI; Cohen J; Alexander B
    BJU Int; 2012 Dec; 110(11):1618-26. PubMed ID: 22458598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
    Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
    BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
    Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
    Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?
    Maulard-Durdux C; Dufour B; Hennequin C; Chrétien Y; Vignes B; Droz D; Delanian S; Housset M
    J Urol; 1996 Jan; 155(1):115-7. PubMed ID: 7490805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
    Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urothelial Carcinoma of the Renal Pelvis and Ureter: Does Location Make a Difference?
    Lwin AA; Hsu CH; Chipollini J
    Clin Genitourin Cancer; 2020 Feb; 18(1):45-49.e1. PubMed ID: 31786118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma: an analysis of 368 radical nephroureterectomy specimens].
    Wang Y; He HY
    Zhonghua Bing Li Xue Za Zhi; 2016 Oct; 45(10):681-686. PubMed ID: 27760608
    [No Abstract]   [Full Text] [Related]  

  • 11. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.
    Rouprêt M; Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Cowan NC; Dominguez-Escrig JL; Gontero P; Hugh Mostafid A; Palou J; Peyronnet B; Seisen T; Soukup V; Sylvester RJ; Rhijn BWGV; Zigeuner R; Shariat SF
    Eur Urol; 2021 Jan; 79(1):62-79. PubMed ID: 32593530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
    Czito B; Zietman A; Kaufman D; Skowronski U; Shipley W
    J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma.
    Li X; Cui M; Gu X; Fang D; Li H; Qin S; Yang K; Zhu T; Li X; Zhou L; Gao XS; Wang D
    World J Surg Oncol; 2020 May; 18(1):114. PubMed ID: 32473636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes.
    Piraino JA; Snow ZA; Edwards DC; Hager S; McGreen BH; Diorio GJ
    Urol Oncol; 2020 Nov; 38(11):851.e1-851.e10. PubMed ID: 32859461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma.
    Silberstein JL; Power NE; Savage C; Tarin TV; Favaretto RL; Su D; Kaag MG; Herr HW; Dalbagni G
    J Urol; 2012 Feb; 187(2):429-34. PubMed ID: 22177163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
    Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
    Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis.
    Yuan H; Chen X; Liu L; Yang L; Pu C; Li J; Bai Y; Han P; Wei Q
    Urol Oncol; 2014 Oct; 32(7):989-1002. PubMed ID: 25082191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.
    Messer JC; Terrell JD; Herman MP; Ng CK; Scherr DS; Scoll B; Boorjian SA; Uzzo RG; Wille M; Eggener SE; Lucas SM; Lotan Y; Shariat SF; Raman JD
    Urol Oncol; 2013 Aug; 31(6):904-8. PubMed ID: 21906967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study.
    Colin P; Ouzzane A; Pignot G; Ravier E; Crouzet S; Ariane MM; Audouin M; Neuzillet Y; Albouy B; Hurel S; Saint F; Guillotreau J; Guy L; Bigot P; De La Taille A; Arroua F; Marchand C; Matte A; Fais PO; Rouprêt M;
    BJU Int; 2012 Oct; 110(8):1134-41. PubMed ID: 22394612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study.
    Xylinas E; Colin P; Audenet F; Phe V; Cormier L; Cussenot O; Houlgatte A; Karsenty G; Bruyère F; Polguer T; Ruffion A; Valeri A; Rozet F; Long JA; Zerbib M; Rouprêt M
    World J Urol; 2013 Feb; 31(1):61-8. PubMed ID: 23053211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.